iiinova — where your digital self keeps evolving

Carlota Rubio-Perez

@carlotarp.bsky.social

105 followers 132 following 9 posts

Postdoctoral researcher | Medical oncology resident @hospitalclinic Immunoncology & bioinformatics

Posts Replies Media

Reposted by Carlota Rubio-Perez

Ming Tommy Tang @tommytang.bsky.social · 22/06/2025

Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform www.cell.com/cell-report...

051

Carlota Rubio-Perez @carlotarp.bsky.social · 30/04/2025

A must read for today's afternoon presented today at #AACR25 by C. Curtis: beatiful through work on classical breast cancer subtypes characterization shows deep similarity between HER2+ and ER+ high risk www.nature.com/articles/s41...

032

Carlota Rubio-Perez @carlotarp.bsky.social · 30/04/2025

Closing plenary session with deeply interesting work presented by C. Curtis and @marleenkok.bsky.social on mTNBC and biomarkers of response to IO: published, almost and ongoing work

020

Reposted by Carlota Rubio-Perez

American Association for Cancer Research (AACR) @theaacr.bsky.social · 28/04/2025

At yesterday's opening ceremony, we asked the cancer community to stand together to make their voices heard in support of innovative cancer science and medicine. #CancerResearchSavesLives® #AACR25

15025

Carlota Rubio-Perez @carlotarp.bsky.social · 28/04/2025

Ingenious strategies by Igne Svane to improve TIL therapy activity based on optimization of antigen recognition: tumor cell reprogramming into DC-like, expansion from tumor fragments #AACR25

010

Carlota Rubio-Perez @carlotarp.bsky.social · 28/04/2025

Great talk on CAR NK potential by Katy Rezvani: potent citotoxicity, unexpected durable response. Amazing clinical trial pipeline at @mdanderson.bsky.social

020

Carlota Rubio-Perez @carlotarp.bsky.social · 28/04/2025

Great work on CAR-T improvement by Marcela Maus: beyond IFNg KO, CRISPR screening libraries in vivo and in vitro to look for the best candidates #AACR25

020

Reposted by Carlota Rubio-Perez

Víctor Albarrán Fernández @vicalbarran.bsky.social · 27/04/2025

Happy to be at #AACR25! Looking forward to witnessing new advances in #Immunotherapy and #CellTherapy 🧬🔬

021

Carlota Rubio-Perez @carlotarp.bsky.social · 27/04/2025

Encouraging pre-clinical results for GBM patients: triple-comb (DXM + antiCSF1 + antiTGFB) inhibitis post RT scarring, a niche for tumor recurrence @johannajoyce.bsky.social #AACR25

020

Carlota Rubio-Perez @carlotarp.bsky.social · 27/04/2025

Second plenary, continuing with genomics. ecDNA old but kind of new for oncologists, relevant clinical implications: resistance to targeted therapies, worse prognosis, immune supressive TME relationship @paulmischel.bsky.social #AACR

000

Carlota Rubio-Perez @carlotarp.bsky.social · 27/04/2025

Kickoff talk of first plenary session on genomic evolution, impressive work: from non tumoral to pre-malignant stages by @imartincorena.bsky.social Bioinformatics opening of #AACR25

040

Carlota Rubio-Perez @carlotarp.bsky.social · 27/04/2025

A way to start with @bsky.app ! 7 days of cutting edge cancer research #AACR25

030